17 results about "Borrelia sp" patented technology

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and / or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present inventors have discovered a substance in Salvia pisidica (Boiss. & Heldr.), a type of sage, that can kill Borrelia and Yersinia bacteria in vitro and in vivo. Until now, it has been thought that the ethanol extract or oil of Salvia pisidica has antibacterial effects against gram-positive bacteria. Previous experiments support this scientific view.

The present invention relates to self-assembling protein nanoparticles displaying an 'outer surface protein A' (OspA) or a mutant 'complement regulator-acquiring surface protein 2' (CspZ) of Borrelia for use in the vaccination against Lyme disease, particularly in combination.

Compositions and methods are provided for the detection, diagnosis and prognosis of Lyme disease (LD), including methods for confirming Borrelia spp. infection by contacting a whole blood sample from a subject suspected of having LD with a plurality of synthetic peptides comprising T cell epitope-containing regions derived from Borrelia proteins expressed at different stages of Lyme disease in vitro, and indirectly detecting LD-specific activated T cells by assaying for the production of indicators of T cell immune response (e.g., interferon-gamma) produced in response to stimulation by the peptides. Also disclosed are methods for predicting the elimination of LD spirochetes in a LD patient who has undergone treatment for LD by contacting a whole blood sample from the subject with peptides comprising specific T cell epitope regions of Borrelia proteins expressed at different stages of Lyme disease, and confirming the absence of Borrelia-specific activated T cells in the sample by the absence of detectable indicators of T cell immune response (e.g., interferon-gamma).

Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD. In particular, the present disclosure relates to machine learning-based techniques for the discovery of biomarkers for detecting and diagnosing LD and the use of those biomarkers. In particular, the disclosure describes short sequences of amino acids (i.e., peptides) and proteins from the B. burgdorferi proteome that can be used for detection of Lyme disease in patient samples.

Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.

This disclosure provides methods and compositions related to messenger ribonucleic acid (mRNA) vaccines for Lyme disease and related methods of prevention. The mRNA vaccines comprise an mRNA comprising an open reading frame(s) encoding for a protein comprising a Borrelia outer surface protein A (OspA) extracellular domain. In some aspects of the disclosure, the mRNA vaccines comprise an mRNA polynucleotide encoding for a single Borrelia outer surface protein A (OspA) extracellular domain. In some aspects of the disclosure, the mRNA vaccines comprise mRNA polynucleotides collectively encoding for at least seven different Borrelia outer surface protein A (OspA) extracellular domains.

The present disclosure relates to a method of diagnosing Lyme disease in a subject comprising measuring the level of B. burgdorferi peptidoglycan or the level of an antibody that specifically binds to B. burgdorferi peptidoglycan (“anti-peptidoglycan agent”). The present disclosure also relates to a method of treating a Lyme disease in a subject in need thereof comprising administering to the subject an antagonist against B. burgdorferi peptidoglycan (e.g., an anti-peptidoglycan antibody or a peptidoglycan-specific hydrolase). Antagonists (e.g., anti-peptidoglycan antibodies) suitable for the present methods are also disclosed.

The present disclosure relates to immunogenic compositions comprising a Borrelia outer surface protein A (OspA) antigen or an RNA polynucleotide encoding the OspA antigen and an adjuvant. In some aspects, the immunogenic compositions are suitable for stimulating an immune response against Borrelia in a subject. The present disclosure also relates to kits of, uses of, and methods of using the immunogenic compositions.

The present disclosure provides a Lyme disease vaccine, comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one bacteria of the genus Borrelia, and methods of eliciting an immune response by administering said vaccine.

Kits, methods, and material for use in detecting tick-borne microorganism(s) are provided herein. One is able to detect DNA from several different species of microorganisms from samples (bodily fluid, tissue, etc.) from ticks and / or mammals to determine if one or more of the microorganisms has infected the tick and / or mammal. The assay uses PCR techniques with a multiple primers and probes. The microorganisms can be in the Borrelial Layer, the Rickettsiales Layer, and / or the Babesial Layer.

The present disclosure relates to immunogenic compositions comprising a. Borrelia outer surface protein C (OspC) antigen or an RNA polynucleotide encoding the OspC antigen, and an adjuvant or adjuvants. In some aspects, the immunogenic composition further comprises a Borrelia outer surface protein A (OspA) antigen or an RNA polynucleotide encoding the OspA antigen. In some aspects, the immunogenic compositions are suitable for stimulating an immune response against Borrelia in a subject. The present disclosure also relates to kits of, uses of, and methods of using the immunogenic compositions.

Disclosed herein are biomarkers and machine learning techniques for identifying biomarkers. In a particular embodiment, the disclosure relates to the identification of biomarkers for use in the detection and diagnosis of LD. In particular, the disclosure relates to the discovery of biomarkers for the detection and diagnosis of LD, as well as machine learning-based techniques for using these biomarkers. In particular, the disclosure describes short amino acid sequences (such as peptides) and proteins from the Borrelia burgdorferi proteome for use in the detection of Lyme disease in patient samples.

Biomarkers and machine learning techniques for identifying biomarkers are disclosed herein. In one particular embodiment, the present disclosure relates to the identification of biomarkers for the detection and diagnosis of LD. In particular, the present disclosure relates to machine learning-based techniques for the discovery of biomarkers for the detection and diagnosis of LD, and uses of these biomarkers. In particular, the present disclosure describes short amino acid sequences (i.e. Peptides) and proteins from Borrelia burgdorferi proteome that can be used to detect Lyme disease in a patient sample.

The present disclosure relates to a method of diagnosing Lyme disease in a subject comprising measuring the level of B. burgdorferi peptidoglycan or the level of an antibody that specifically binds to B. burgdorferi peptidoglycan (“anti-peptidoglycan agent”). The present disclosure also relates to a method of treating a Lyme disease in a subject in need thereof comprising administering to the subject an antagonist against B. burgdorferi peptidoglycan (e.g., an anti-peptidoglycan antibody or a peptidoglycan-specific hydrolase). Antagonists (e.g., anti-peptidoglycan antibodies) suitable for the present methods are also disclosed.